Trial Profile
A Phase 3, Prospective, Randomized, Double-blind, Multi-center Study of the Efficacy and Safety of Lanreotide Autogel/Depot 120 mg Plus BSC vs. Placebo Plus BSC for Tumour Control in Subjects With Well Differentiated, Metastatic and/or Unresectable, Typical or Atypical, Lung Neuroendocrine Tumours
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 11 Jul 2022
Price :
$35
*
At a glance
- Drugs Lanreotide (Primary)
- Indications Lung cancer; Neuroendocrine tumours
- Focus Therapeutic Use
- Acronyms SPINET
- Sponsors Ipsen
- 10 Apr 2022 This trial has been completed in Spain (Global end date: 28-02-2020), according to European Clinical Trials Database record.
- 08 Mar 2022 According to an Ipsen media release, data published in 19th Annual European Neuroendocrine Tumor Society (ENETS) Conference.
- 30 Sep 2021 Status changed from completed to discontinued.